Abbott Labs delivered a second-quarter earnings beat on Thursday, but the company's ongoing litigation over its baby formula — plus softer guidance for the current quarter — is dragging down shares. We view the pullback as an opportunity. Revenue for the three months ended June 30 rose 4% year over year to $10.38 billion, slightly ahead of expectations, according to LSEG. On an organic basis, sales were up 9.3% versus the year-ago period , also ahead of expectations.
Abbott Chairman of the Board and CEO Robert B. Ford delivers a keynote address at CES 2022 at The Venetian Las Vegas on January 6, 2022 in Las Vegas, Nevada.delivered a second-quarter earnings beat on Thursday, but the company's ongoing litigation over its baby formula — plus softer guidance for the current quarter — is dragging down shares. We view the pullback as an opportunity.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »
출처: AP - 🏆 728. / 51 더 많은 것을 읽으십시오 »
출처: wjxt4 - 🏆 246. / 63 더 많은 것을 읽으십시오 »
출처: ksatnews - 🏆 442. / 53 더 많은 것을 읽으십시오 »